During the past decade, National University Hospital; National University Cancer Institute, Singapore (NCIS) conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 12 clinical trials were completed, i.e. on average, 38.7% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 7 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National University Hospital; National University Cancer Institute, Singapore (NCIS)" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "Cancer Therapeutics Research Group" with 3 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored, "Gamida Cell ltd" with 3 trials sponsored and "Genentech, Inc." with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National University Hospital; National University Cancer Institute, Singapore (NCIS)" #1 collaborator was "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator, "ADIR, a Servier Group company" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Cancer Science Institute of Singapore" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "National University Hospital; National University Cancer Institute, Singapore (NCIS)" are "Breast Cancer" (3 trials), "Myelodysplastic Syndrome (MDS)" (3 trials), "Non-Small Cell Lung Cancer" (3 trials), "Acute Lymphoblastic Leukemia (ALL)" (2 trials) and "Acute Myeloid Leukemia (AML)" (2 trials). Many other conditions were trialed in "National University Hospital; National University Cancer Institute, Singapore (NCIS)" in a lesser frequency.

Most popular intervention types in "National University Hospital; National University Cancer Institute, Singapore (NCIS)" are "Drug" (37 trials), "Biological" (2 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (7 trials), "Placebo" (7 trials), "Carboplatin" (5 trials), "Gemcitabine" (5 trials) and "Paclitaxel" (5 trials). Other intervention names were less common.

The vast majority of trials in "National University Hospital; National University Cancer Institute, Singapore (NCIS)" are 38 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "National University Hospital; National University Cancer Institute, Singapore (NCIS)". undefined are not yet recruiting, 12 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in National University Hospital; National University Cancer Institute, Singapore (NCIS), undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in National University Hospital; National University Cancer Institute, Singapore (NCIS), 7 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

National University Hospital; National University Cancer Institute, Singapore (NCIS) has several departments that took part in Clinical trials: "Cancer Therapeutics Research Group" - 2 trials, "Department of Hematology-Oncology, National University Hospital" - 2 trials